Journal article
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
Abstract
BACKGROUND: Tumour necrosis factor (TNF)-antagonists have an established role in the treatment of inflammatory bowel diseases (IBDs), however, subtherapeutic drug levels and the formation of anti-drug antibodies (ADAs) may decrease their efficacy.
AIM: The evidence supporting the use of therapeutic drug monitoring (TDM) based clinical algorithms for infliximab (IFX) and their role in clinical practice will be discussed.
Authors
Khanna R; Sattin BD; Afif W; Benchimol EI; Bernard E; Bitton A; Bressler B; Fedorak RN; Ghosh S; Greenberg GR
Journal
Alimentary Pharmacology & Therapeutics, Vol. 38, No. 5, pp. 447–459
Publisher
Wiley
Publication Date
9 2013
DOI
10.1111/apt.12407
ISSN
0269-2813